AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
AbbVie(ABBV) stock is priced at $236.28, giving the company a market capitalization of 417.77B. It carries a P/E multiple of 178.28 and pays a dividend yield of 2.8%.
As of 2025-11-22, AbbVie(ABBV) stock has fluctuated between $230.14 and $238.00. The current price stands at $236.28, placing the stock +2.7% above today's low and -0.7% off the high.
The AbbVie(ABBV)'s current trading volume is 8.02M, compared to an average daily volume of 6.25M.
In the last year, AbbVie(ABBV) shares hit a 52-week high of $244.81 and a 52-week low of $164.39.
In the last year, AbbVie(ABBV) shares hit a 52-week high of $244.81 and a 52-week low of $164.39.
ABBV News
In November 2025, AbbVie received full FDA approval for EPKINLY (epcoritamab-bysp) in combination with rituximab and lenalidomide for the treatment of relapsed...
Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model ba...
2 Dividend Stocks to Hold Through Any Market Cycle Quick Read AbbVie (ABBV) is up 36% year-to-date and 187% over the last five years. AbbVie pays a $6.92 annu...
Analyst ratings
66%
of 32 ratingsMore ABBV News
AbbVie (ABBV) announced that EPKINLY, a T-cell engaging bispecific antibody administered subcutaneously, in combination with rituximab and lenalidomide is appro...
The board of AbbVie Inc. ( ) has announced that it will be paying its dividend of $1.73 on the 17th of February, an increased payment from last year's comparabl...
(RTTNews) - AbbVie (ABBV) announced that a new 6-month 45mg LUPRON DEPOT, or leuprolide acetate for extended-release injectable suspension, strength has receive...
AbbVie (ABBV) announced that a new 6-month 45mg Lupron Depot strength has received Health Canada approval for the treatment of advanced prostate cancer. Lupron...
It's no reason to stay up at night. Earnings season creates short-term winners and losers, companies whose shares rise or fall after they announce their quarte...
Healthcare stocks have far outperformed the broader market over the past month. The healthcare sector has been on fire in recent weeks. The S&P 500 Healthcare...
